Biogen Inc
NASDAQ:BIIB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
165.79
267.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Biogen Inc
Wall Street
Price Targets
BIIB Price Targets Summary
Biogen Inc
According to Wall Street analysts, the average 1-year price target for
BIIB
is 267.82 USD
with a low forecast of 191.9 USD and a high forecast of 359.1 USD.
BIIB Last Price Targets
Biogen Inc
The latest public price target was made on Oct 31, 2024 by
Terence Flynn
from
Morgan Stanley
,
who expects
BIIB
stock to
rise by 23%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Terence Flynn
Morgan Stanley
|
204
USD
Upside 23% |
2 weeks ago
Oct 31, 2024
|
Biogen downgraded to Equal Weight from Overweight at Morgan Stanley
TheFly
|
Jay Olson
Oppenheimer
|
255
USD
Upside 54% |
2 weeks ago
Oct 31, 2024
|
Biogen (BIIB) PT Lowered to $255 at Oppenheimer
StreetInsider
|
Salveen Richter
Goldman Sachs
|
290
USD
Upside 75% |
2 weeks ago
Oct 30, 2024
|
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
StreetInsider
|
Christopher Raymond
Raymond James
|
315
USD
Upside 90% |
2 weeks ago
Oct 30, 2024
|
Biogen (BIIB) PT Raised to $315 at Piper Sandler
StreetInsider
|
Evan Seigerman
BMO Capital
|
230
USD
Upside 39% |
4 weeks ago
Oct 17, 2024
|
Biogen price target lowered to $230 from $260 at BMO Capital
TheFly
|
Ashwani Verma
UBS
|
202
USD
Upside 22% |
1 month ago
Oct 3, 2024
|
Biogen price target lowered to $202 from $234 at UBS
TheFly
|
Laura Chico
Wedbush
|
205
USD
Upside 24% |
1 month ago
Sep 23, 2024
|
Biogen price target lowered to $205 from $210 at Wedbush
TheFly
|
Brian Skorney
Robert W. Baird
|
294
USD
Upside 77% |
3 months ago
Jul 29, 2024
|
Biogen (BIIB) PT Lowered to $294 at Baird
StreetInsider
|
|
Salveen Richter
Goldman Sachs
|
342
USD
Upside 106% |
3 months ago
Jul 26, 2024
|
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
StreetInsider
|
Brian Abrahams
RBC Capital
|
282
USD
Upside 70% |
3 months ago
Jul 26, 2024
|
Biogen (BIIB) PT Lowered to $282 at RBC Capital
StreetInsider
|
Christopher Raymond
Piper Sandler
|
307
USD
Upside 85% |
3 months ago
Jul 26, 2024
|
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
StreetInsider
|
|
Christopher Raymond
Piper Sandler
|
313
USD
Upside 89% |
4 months ago
Jul 12, 2024
|
Biogen price target lowered to $313 from $335 at Piper Sandler
TheFly
|
|
Terence Flynn
Morgan Stanley
|
311
USD
Upside 88% |
4 months ago
Jul 11, 2024
|
Biogen price target lowered to $311 from $331 at Morgan Stanley
TheFly
|
George Farmer
Scotiabank
|
275
USD
Upside 66% |
5 months ago
Jun 12, 2024
|
Scotiabank Reiterates Sector Outperform Rating on Biogen (BIIB)
StreetInsider
|
|
Evan David Seigerman
BMO Capital
|
260
USD
Upside 57% |
5 months ago
May 23, 2024
|
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
StreetInsider
|
Paul Matteis
Stifel Nicolaus
|
275
USD
Upside 66% |
5 months ago
May 22, 2024
|
Stifel Reiterates Buy Rating on Biogen (BIIB) Following Acquisition of HI-Bio
StreetInsider
|
|
Matthew Harrison
Morgan Stanley
|
331
USD
Upside 100% |
5 months ago
May 22, 2024
|
Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio
StreetInsider
|
|
Christopher Raymond
Raymond James
|
335
USD
Upside 102% |
5 months ago
May 22, 2024
|
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-Bio
StreetInsider
|
|
Laura Chico
Wedbush
|
215
USD
Upside 30% |
6 months ago
Apr 25, 2024
|
Biogen price target raised to $215 from $213 at Wedbush
TheFly
|
|
Andrew Fein
H.C. Wainwright
|
300
USD
Upside 81% |
6 months ago
Apr 25, 2024
|
Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
StreetInsider
|
|
Brian Abrahams
RBC Capital
|
317
USD
Upside 91% |
6 months ago
Apr 25, 2024
|
Biogen (BIIB) PT Lowered to $317 at RBC Capital
StreetInsider
|
|
Jay Olson
Oppenheimer
|
270
USD
Upside 63% |
6 months ago
Apr 19, 2024
|
Biogen (BIIB) PT Lowered to $270 at Oppenheimer
StreetInsider
|
Carter Gould
Barclays
|
215
USD
Upside 30% |
7 months ago
Apr 3, 2024
|
Biogen price target lowered to $215 from $230 at Barclays
TheFly
|
|
Laura Chico
Wedbush
|
269
USD
Upside 62% |
1 year ago
Aug 7, 2023
|
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
Benzinga
|
Yatin Suneja
Guggenheim
|
350
USD
Upside 111% |
1 year ago
May 1, 2023
|
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BIIB's stock price target?
Price Target
267.82
USD
According to Wall Street analysts, the average 1-year price target for
BIIB
is 267.82 USD
with a low forecast of 191.9 USD and a high forecast of 359.1 USD.
What is Biogen Inc's Revenue forecast?
Projected CAGR
0%
For the last 8 years the
compound annual growth rate for
Biogen Inc's revenue is
-1%.
The projected
CAGR
for the next 3 years is
0%.
What is Biogen Inc's Operating Income forecast?
Projected CAGR
15%
For the last 8 years the
compound annual growth rate for
Biogen Inc's operating income is
-10%.
The projected
CAGR
for the next 3 years is
15%.
What is Biogen Inc's Net Income forecast?
Projected CAGR
31%
For the last 8 years the
compound annual growth rate for
Biogen Inc's net income is
-13%.
The projected
CAGR
for the next 3 years is
31%.
You don't have any saved screeners yet
